Beta Bionics (NASDAQ:BBNX) Shares Up 5.6% – Time to Buy?

Beta Bionics, Inc. (NASDAQ:BBNX) was up 5.6% on Monday . The company traded as high as $17.32 and last traded at $17.5050. 588,782 shares changed hands during mid-day trading, a decline of 48% from the average daily volume of 1,137,547 shares. The stock had previously closed at $16.57.

Key Headlines Impacting Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: The FDA cleared Mint, a patch pump with a reusable/disposable design, no recharging requirement, compatibility with leading continuous glucose monitors, and smartphone control through iOS and Android. The product is expected to broaden Beta Bionics’ addressable insulin-delivery market, with a commercial launch planned for 2027. Beta Bionics Mint FDA clearance announcement
• Positive Sentiment: Beta Bionics also unveiled 3D Intelligence, its next-generation insulin-dosing algorithm. The technology could strengthen the company’s product pipeline and support longer-term growth if it improves automated insulin delivery. Beta Bionics 3D Intelligence announcement
• Positive Sentiment: Beta Bionics and Senseonics announced plans to integrate Senseonics’ year-long Eversense 365 continuous glucose monitor with the iLet Bionic Pancreas. The combined system is targeted for commercial launch in the fourth quarter of 2026, potentially improving the iLet ecosystem and patient adoption. Senseonics and Beta Bionics partnership
• Negative Sentiment: Despite the FDA clearance, reports indicate that Beta Bionics cut its 2026 outlook. Lower near-term expectations could temper investor enthusiasm and raise concerns about commercialization timing or demand. Beta Bionics cuts 2026 outlook
• Negative Sentiment: Several law firms are promoting a securities-fraud class action alleging investor losses tied to potential device-safety disclosures. The litigation remains an allegation, but it creates legal, reputational, and potential financial risks for BBNX. Beta Bionics securities lawsuit

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on BBNX. Weiss Ratings upgraded shares of Beta Bionics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 18th. Truist Financial upped their price target on shares of Beta Bionics from $18.00 to $22.00 and gave the company a “buy” rating in a report on Monday, July 13th. Bank of America reduced their price objective on shares of Beta Bionics from $23.00 to $11.00 and set a “neutral” rating for the company in a research report on Monday, May 18th. The Goldman Sachs Group boosted their target price on shares of Beta Bionics from $17.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Finally, UBS Group initiated coverage on shares of Beta Bionics in a research note on Tuesday, July 28th. They set a “buy” rating and a $22.00 target price for the company. Seven investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Beta Bionics currently has a consensus rating of “Moderate Buy” and an average price target of $20.40.

Beta Bionics Trading Up 3.2%

The firm has a market cap of $769.55 million, a price-to-earnings ratio of -10.38 and a beta of 3.37. The stock has a 50-day moving average of $17.29 and a two-hundred day moving average of $13.80.

Beta Bionics (NASDAQ:BBNX) last posted its quarterly earnings data on Wednesday, July 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.09. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%.The firm had revenue of $32.01 million for the quarter. Sell-side analysts expect that Beta Bionics, Inc. will post -2.1 EPS for the current fiscal year.

Insider Activity

In related news, insider Mark Hopman sold 36,870 shares of the company’s stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $18.46, for a total value of $680,620.20. Following the completion of the sale, the insider owned 87,157 shares in the company, valued at approximately $1,608,918.22. This represents a 29.73% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mike Mensinger sold 4,375 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $19.11, for a total transaction of $83,606.25. Following the completion of the transaction, the insider directly owned 180,040 shares of the company’s stock, valued at $3,440,564.40. This represents a 2.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 70,132 shares of company stock worth $1,284,623 over the last three months. 5.30% of the stock is owned by insiders.

Hedge Funds Weigh In On Beta Bionics

Several institutional investors and hedge funds have recently bought and sold shares of BBNX. Strs Ohio acquired a new position in shares of Beta Bionics in the 1st quarter valued at about $29,000. Summit Securities Group LLC acquired a new stake in shares of Beta Bionics during the fourth quarter worth approximately $52,000. Legal & General Group Plc boosted its holdings in shares of Beta Bionics by 197.4% during the second quarter. Legal & General Group Plc now owns 3,976 shares of the company’s stock worth $58,000 after purchasing an additional 2,639 shares during the period. Caitong International Asset Management Co. Ltd grew its position in Beta Bionics by 1,075.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock valued at $61,000 after purchasing an additional 1,818 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Beta Bionics during the first quarter valued at approximately $95,000.

Beta Bionics Company Profile

Beta Bionics, Inc is a medical technology company focused on developing automated insulin-delivery systems for people with diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to simplify diabetes management by using continuous glucose monitoring data to adjust insulin dosing with limited user input.

The iLet Bionic Pancreas received clearance from the U.S. Food and Drug Administration in 2023 for use by people with type 1 diabetes.